Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
AssigneeOmeros Medical Systems, Inc.
InventorsGregory A. Demopulos, Pamela A. Pierce, Jeffrey M. Herz
Life of this patent
Estimating the term…
Loading patent…
AssigneeOmeros Medical Systems, Inc.
InventorsGregory A. Demopulos, Pamela A. Pierce, Jeffrey M. Herz
Estimating the term…
A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. The solution is introduced luminally to continuously irrigate an arterial site during an operative/interventional or diagnostic procedure for preemptive inhibition of pain and inflammation, vascular and non-vascular smooth muscle spasm, and restenosis while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain, inflammation, vasospasm and restenosis includes a serotonin2 antagonist, a cyclooxygenase inhibitor, an endothelin antagonist, an ATP-sensitive K+ channel antagonist, a Ca2+ channel antagonist, a nitric oxide donor, an anti-thrombin agent, a glycoprotein IIb/IIIa receptor blocker, a PKC inhibitor and a protein tyrosine kinase inhibitor.
A solution comprising a plurality of agents selected from the group consisting of pain/inflammation inhibitory agents, spasm inhibitory agents and restenosis inhibitory agents in a liquid carrier adapted for perioperative delivery to an operative vascular site, wherein each of the agents is included at a concentration of no greater than 100,000 nanomolar, wherein the agents are selected to act on a plurality of differing molecular targets, and wherein the solution includes at least one restenosis inhibitory agent selected from the group consisting of:
A solution comprising a plurality of restenosis inhibitory agents in a liquid carrier adapted for perioperative delivery to an operative vascular site, wherein the agents are selected to act on a plurality of differing molecular targets, wherein each of the agents is included at a concentration of no greater than 100,000 nanomolar, and wherein each of the agents is selected from the group consisting of:
Dependencies are inferred from the claim text.